TRPV1 and atopic eczema: Topical TRPV1 antagonist PAC-14028 has been assessed in phase II randomized controlled trials for the treatment of mild to moderate atopic dermatitis, showing significant reduction in pruritus-related VAS scores by week 8 [36].